- Home
- ACB vs NMRA Comparison
ACB vs NMRA Comparison
Compare ACB & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- NMRA
- Stock Information
- Founded
- ACB 2013
- NMRA 2019
- Country
- ACB Canada
- NMRA United States
- Employees
- ACB N/A
- NMRA N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- NMRA
- Sector
- ACB Health Care
- NMRA
- Exchange
- ACB Nasdaq
- NMRA Nasdaq
- Market Cap
- ACB 256.5M
- NMRA 268.5M
- IPO Year
- ACB N/A
- NMRA 2023
- Fundamental
- Price
- ACB $4.99
- NMRA $1.45
- Analyst Decision
- ACB
- NMRA Hold
- Analyst Count
- ACB 0
- NMRA 8
- Target Price
- ACB N/A
- NMRA $5.83
- AVG Volume (30 Days)
- ACB 1.1M
- NMRA 376.8K
- Earning Date
- ACB 11-05-2025
- NMRA 11-11-2025
- Dividend Yield
- ACB N/A
- NMRA N/A
- EPS Growth
- ACB N/A
- NMRA N/A
- EPS
- ACB N/A
- NMRA N/A
- Revenue
- ACB $262,403,032.00
- NMRA N/A
- Revenue This Year
- ACB $9.42
- NMRA N/A
- Revenue Next Year
- ACB $3.01
- NMRA N/A
- P/E Ratio
- ACB N/A
- NMRA N/A
- Revenue Growth
- ACB 28.58
- NMRA N/A
- 52 Week Low
- ACB $3.42
- NMRA $0.61
- 52 Week High
- ACB $6.91
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- ACB 50.53
- NMRA 36.91
- Support Level
- ACB $4.87
- NMRA $1.48
- Resistance Level
- ACB $5.11
- NMRA $1.70
- Average True Range (ATR)
- ACB 0.21
- NMRA 0.10
- MACD
- ACB -0.02
- NMRA -0.03
- Stochastic Oscillator
- ACB 23.65
- NMRA 7.21
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.